Title: Sandy Fabre: Innovator in Cognitive and Cannabinoid-Related Treatments
Introduction
Sandy Fabre is a notable inventor based in France, recognized for her contributions to the field of cognitive and cannabinoid-related disorders. With a focus on developing specific pregnenolone derivatives, her work aims to address significant health challenges.
Latest Patents
Sandy Fabre holds several patents, including:
1. **3.beta.-(benzyloxy)-17.alpha.-Methyl-Pregn-5-En-20-One For Use In The Treatment Of Cognitive Disorders** - This invention relates to a specific pregnenolone derivative designed for the treatment of cognitive disorders. The compound is noted for its potency in correcting cognitive impairments observed in such disorders.
2. **3Beta-(4-METHOXYBENZYLOXY)PREGN-5-En-20-One For Use In The Treatment Of Cannabinoids-Related Disorders** - This patent focuses on a pregnenolone derivative aimed at treating cannabinoid-related disorders. The compound effectively inhibits the effects of THC, demonstrating significant potential in both unconditioned and conditioned responses in non-human primates.
Career Highlights
Throughout her career, Sandy has worked with prominent organizations such as Inserm and Alienor Farma. Her research has contributed to advancements in understanding and treating cognitive and cannabinoid-related disorders.
Collaborations
Sandy Fabre has collaborated with various professionals in her field, including her coworker Pier Vincenzo Piazza, who has also made significant contributions to research in related areas.
Conclusion
Sandy Fabre's innovative work in developing treatments for cognitive and cannabinoid-related disorders highlights her commitment to advancing medical science. Her patents reflect a dedication to improving health outcomes through targeted therapies.